Backlash: Harvard experts fret over the fallout from FDA’s OK for Sarepta’s controversial Duchenne drug
Two of Harvard’s top FDA policy experts, Aaron Kesselheim and Jerry Avorn, have expressed some deep concerns about the agency’s approval of eteplirsen, OK’d to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
